Previous 10 | Next 10 |
- Announced Independent Data Monitoring Committee’s (IDMC) Recommendation to Continue the Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Without Modifications: IDMC to Reconvene in June - - Completed Enrollment in Phase 3 REGAL Study of Galinpepimut-S - ...
2024-05-07 08:00:00 ET Summary Welcome to another installment of our monthly Rare Stock Picks series. Today, we're highlighting April 2024 investment picks you may have missed. As you know, some Seeking Alpha analysts are more discerning by nature. Others are finding compelling id...
2024-05-01 10:23:01 ET More on SELLAS Life Sciences, TG Therapeutics, etc. Sellas Life Sciences Group: A Lottery Ticket With An Estimated 6x Payout TG Therapeutics: The Cloud Over Briumvi TG Therapeutics: BRIUMVI Development Could Lead To Great Results TG The...
- The Company Filed IP Protection Related to the ASXL1 Mutation, a Highly Prevalent Gene Mutation in Myeloid Malignancies and Solid Tumors With Significant Market Potential – - 100% Overall Response Rate in Patients with ASXL1 Mutation in the SLS009 30mg BIW Cohort to Date, Al...
2024-04-29 08:54:27 ET More on SELLAS Life Sciences Sellas Life Sciences Group: A Lottery Ticket With An Estimated 6x Payout SELLAS Life Sciences GAAP EPS of -$1.34 misses by $0.24 SELLAS Life Sciences looks to raise $20M in a direct offering Seeking Alpha...
– Based on the Efficacy and Safety Data Assessed, the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3 REGAL Trial Patients Treatment and Follow-Up Without Any Modifications – – IDMC Will Convene Again Ahead of Scheduled IDMC Charter M...
2024-04-19 13:49:43 ET Summary SELLAS Life Sciences Group, Inc. is a late-stage biotech company with a leading drug candidate, Galinpepimut-S, or GPS, that has a 44% probability of success and a potential 9x return. GPS is an immunotherapy drug targeting the Wilms Tumor 1 antigen,...
2024-03-28 16:57:07 ET More on SELLAS Life Sciences SELLAS Life Sciences looks to raise $20M in a direct offering Sellas Life Sciences gains on securing orphan drug status for r/r PTCL treatment Seeking Alpha’s Quant Rating on SELLAS Life Sciences Hist...
2024-03-28 16:54:11 ET More on SELLAS Life Sciences SELLAS Life Sciences looks to raise $20M in a direct offering Sellas Life Sciences gains on securing orphan drug status for r/r PTCL treatment Seeking Alpha’s Quant Rating on SELLAS Life Sciences Re...
Announced Phase 2a study of SLS009 in r/r AML Showing 50% Response Rate in the Selected Optimal Dose of 30 mg BIW Exceeding the Targeted 20% and 100% Response Rate in Patients with Identified Biomarkers - Completed Enrollment in Phase 3 REGAL Study of Galinpepimut-S in Patients with Acute...
News, Short Squeeze, Breakout and More Instantly...
SELLAS Life Sciences Group Inc. Company Name:
SLS Stock Symbol:
NASDAQ Market:
SELLAS Life Sciences Group Inc. Website:
- Acute Lymphoblastic Leukemia (ALL) is the Most Common Type of Cancer in Children – - Rare Pediatric Disease Designation (RPDD) Provides Eligibility for SLS009 to Receive a Priority Review Voucher (PRV) Upon Marketing Approval that can be Transferred/Sold to Other Parties – ...
2024-06-18 10:10:00 ET June 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform covering biotech and medical technology stocks releases the second of a two-part series looking at developments for the treatment of blood cancers, including AML, featuring A...
A look at the top 10 most actives in the United States Mustang Bio Inc. (MBIO) rose 141.4% to $0.3138 on volume of 161,736,322 shares ENDRA Life Sciences Inc. (NDRA) rose 13.7% to $0.117778 on volume of 79,058,950 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 27.2% to $0.1042 on volum...